Health3 hours ago
Neurizon Delays IND Decision Citing FDA Strain; $126M Fund Announced
Neurizon Therapeutics has announced a delay in the decision regarding its Investigational New Drug (IND) application, attributing the setback to “strain” within the U.S. Food and...